Oligopeptidase B and B2: comparative modelling and virtual screening as searching tools for new antileishmanial compounds.

Article Details

Citation
Copy to clipboard

Sodero AC, Dos Santos AC, Mello JF, DE Jesus JB, DE Souza AM, Rodrigues MI, DE Simone SG, Rodrigues CR, DE Matos Guedes HL

Oligopeptidase B and B2: comparative modelling and virtual screening as searching tools for new antileishmanial compounds.

Parasitology. 2017 Apr;144(4):536-545. doi: 10.1017/S0031182016002237. Epub 2016 Dec 29.

PubMed ID
28031079 [ View in PubMed
]
Abstract

Leishmaniasis are diseases caused by parasites of the genus Leishmania and transmitted to humans by the bite of infected insects of the subfamily Phlebotominae. Current drug therapy shows high toxicity and severe adverse effects. Recently, two oligopeptidases (OPBs) were identified in Leishmania amazonensis, namely oligopeptidase B (OPB) and oligopeptidase B2 (OPB2). These OPBs could be ideal targets, since both enzymes are expressed in all parasite lifecycle and were not identified in human. This work aimed to identify possible dual inhibitors of OPB and OPB2 from L. amazonensis. The three-dimensional structures of both enzymes were built by comparative modelling and used to perform a virtual screening of ZINC database by DOCK Blaster server. It is the first time that OPB models from L. amazonensis are used to virtual screening approach. Four hundred compounds were identified as possible inhibitors to each enzyme. The top scored compounds were submitted to refinement by AutoDock program. The best results suggest that compounds interact with important residues, as Tyr490, Glu612 and Arg655 (OPB numbers). The identified compounds showed better results than antipain and drugs currently used against leishmaniasis when ADMET in silico were performed. These compounds could be explored in order to find dual inhibitors of OPB and OPB2 from L. amazonensis.

DrugBank Data that Cites this Article

Drugs